The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
India's semaglutide market is heating up with more than 50 brands poised to launch post-patent. But experts warn of a measured rollout due to the drug's intricate manufacturing demands. Inside the scramble for affordable GLP-1 access in a diabetes hotspot.
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
Wegovy, Ozempic, and Mounjaro promise effortless weight loss with minimal risk, but new research uncovers deeper dangers like altered brain chemistry and loss of desire. On The Spectacle Podcast, Scott McKay and Melissa Mackenzie dive into the science, Melissa's personal story, and why lifestyle changes offer a safer path.
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
As GLP-1 drugs like Ozempic transform weight loss, biotech startup Lembas argues biopeptides can reclaim a role through food-based satiety support. CEO Shay Hillel, speaking at Future Food-Tech San Francisco, positions these short proteins as complements—not replacements—for better metabolic health. With clinical trials underway, functional foods may soon enhance GLP-1 therapy.
As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.
Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.
